Cytophenix is a biotechnology company developing rapid antimicrobial susceptibility testing (AST) technology, FloCAST™, which provides same-day results to guide antibiotic and antifungal treatment decisions. By delivering AST results within 4 hours—up to 72 hours faster than traditional methods—Cytophenix supports healthcare professionals in effectively treating serious infections and combating antimicrobial resistance. Headquartered in Perth, Western Australia, Cytophenix leverages AI-powered solutions and advanced flow cytometry to improve clinical outcomes and preserve antibiotic efficacy.